These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20847555)

  • 1. Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease.
    Yakushev I; Bartenstein P; Siessmeier T; Hiemke C; Scheurich A; Lotz J; Fellgiebel A; Müller MJ
    Dement Geriatr Cogn Disord; 2010; 30(3):245-53. PubMed ID: 20847555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
    Yakushev I; Muller MJ; Buchholz HG; Lang U; Rossmann H; Hampel H; Schreckenberger M; Fellgiebel A
    Curr Alzheimer Res; 2012 Feb; 9(2):241-7. PubMed ID: 22044023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment.
    Fellgiebel A; Siessmeier T; Scheurich A; Winterer G; Bartenstein P; Schmidt LG; Müller MJ
    Biol Psychiatry; 2004 Aug; 56(4):279-83. PubMed ID: 15312816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease.
    Haense C; Buerger K; Kalbe E; Drzezga A; Teipel SJ; Markiewicz P; Herholz K; Heiss WD; Hampel H
    Eur J Neurol; 2008 Nov; 15(11):1155-62. PubMed ID: 18803648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
    Schmand B; Eikelenboom P; van Gool WA;
    J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early alzheimer disease in patients of a memory clinic.
    Scheurich A; Muller MJ; Siessmeier T; Bartenstein P; Schmidt LG; Fellgiebel A
    Dement Geriatr Cogn Disord; 2005; 20(5):271-7. PubMed ID: 16158009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment.
    Fellgiebel A; Scheurich A; Bartenstein P; Müller MJ
    Psychiatry Res; 2007 Jul; 155(2):167-71. PubMed ID: 17531450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
    JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.
    Okamura N; Arai H; Maruyama M; Higuchi M; Matsui T; Tanji H; Seki T; Hirai H; Chiba H; Itoh M; Sasaki H
    Am J Psychiatry; 2002 Mar; 159(3):474-6. PubMed ID: 11870015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease.
    Vukovich R; Perneczky R; Drzezga A; Förstl H; Kurz A; Riemenschneider M
    Dement Geriatr Cogn Disord; 2009; 27(5):474-80. PubMed ID: 19439965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
    Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
    J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.
    Mitchell AJ
    J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):966-75. PubMed ID: 19465413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual Rating and Computer-Assisted Analysis of FDG PET in the Prediction of Conversion to Alzheimer's Disease in Mild Cognitive Impairment.
    Kang JM; Lee JY; Kim YK; Sohn BK; Byun MS; Choi JE; Son SK; Im HJ; Lee JH; Ryu YH; Lee DY
    Mol Diagn Ther; 2018 Aug; 22(4):475-483. PubMed ID: 29761365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.